Research programme: conduction system disorder protein therapies - BioCardia
Latest Information Update: 16 Jul 2016
At a glance
- Originator BioCardia
- Mechanism of Action Protein modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Conduction disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Conduction-disorders in USA
- 13 Mar 2007 Preclinical trials in Conduction disorders in USA (unspecified route)